Can-fite Biopharma LTD

Form 4F-120-F13G

Insider Trading (Form 4)

AMEX
CANF
Can-fite Biopharma LTD
Form 4: Can-Fite BioPharma: Motti Farbstein Reports Option Grant
Motti Farbstein, CEO, CFO, and COO of Can-Fite BioPharma Ltd., reported the acquisition of 24,000 stock options with an exercise price of $2.04.
AMEX
CANF
Can-fite Biopharma LTD
Form 4: Can-Fite BioPharma Director Acquires Options
Pnina Fishman, a Director and Chief Scientific Officer at Can-Fite BioPharma Ltd., has acquired 24,000 stock options.

Schedule 13G - Passive Investments

AMEX
CANF
Can-fite Biopharma LTD
SCHEDULE 13G/A: Orca Capital AG Discloses 4.1% Stake in Can-Fite BioPharma Following Recent Offering
Orca Capital AG has filed an amended Schedule 13G, reporting a 4.1% beneficial ownership stake in Can-Fite BioPharma Ltd., calculated after the issuer's recent registered offering.
Capital raise
AMEX
CANF
Can-fite Biopharma LTD
SCHEDULE 13G: Orca Capital AG Discloses 9.7% Stake in Can-Fite BioPharma Ltd.
Orca Capital AG has reported a 9.7% beneficial ownership stake in Can-Fite BioPharma Ltd., holding 375 million ordinary shares.
AMEX
CANF
Can-fite Biopharma LTD
SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 4.99% Stake in Can-Fite BioPharma Ltd.
Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a beneficial ownership of 4.99% of Can-Fite BioPharma Ltd.'s common stock as of December 31, 2024.